Comparative Pharmacology
Head-to-head clinical analysis: FML versus INFLAMASE MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML versus INFLAMASE MILD.
FML vs INFLAMASE MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to inhibition of phospholipase A2 via annexin-1 induction, reducing prostaglandin and leukotriene synthesis; also suppresses cytokine production and inflammatory cell migration.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
Fluorometholone ophthalmic suspension 0.1%: Instill 1 drop into conjunctival sac 2-4 times daily. In severe conditions, may increase to 1 drop every hour initially.
N/A
None Documented
None Documented
The terminal elimination half-life of fluorometholone is approximately 1.5 hours in plasma. Clinically, this short half-life allows for multiple daily dosing; however, ocular administration results in sustained local effects due to corneal binding.
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
FML (fluorometholone) is primarily metabolized in the liver, with metabolites excreted renally. Approximately 70-80% of the dose is eliminated in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 10%.
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid